Myeloproliferative Neoplasms | Specialty

The myeloproliferative neoplasms condition center is a comprehensive resource for clinical news on myeloproliferative neoplasms. Read more at OncLive.

Dr Iyer on the Design of the COMMANDS Trial in Lower-Risk MDS With Anemia

May 1st 2024

Sunil Iyer, MD, discusses the design of the phase 3 COMMANDS trial in patients with lower-risk myelodysplastic syndrome with anemia.

Expansion of Luspatercept Indication Underscores Evolving Treatment Landscape for Low-Risk MDS

April 30th 2024

Benjamin Tomlinson, MD, discusses the first-line approval of luspatercept and other ongoing research in low-risk MDS.

Dr Jain on the VERONA Study in Higher-Risk MDS

April 30th 2024

Akriti Jain, MD, discusses the phase 1b VERONA study of venetoclax plus azacitidine in higher-risk myelodysplastic syndromes.

Dr Jurcic on the Use of JAK Inhibitors in Myelofibrosis Management

April 26th 2024

Joseph G. Jurcic, MD, discusses the use of JAK inhibitors in the management of myelofibrosis.

Dr Jain on Unmet Needs in the Treatment of Low- and High-Risk MDS

April 25th 2024

Akriti Jain, MD, discusses unmet needs in patients with low- and high-risk myelodysplastic syndromes.

Dr Jain on the Long-Term Investigation of Luspatercept in Anemic MDS

April 17th 2024

Akriti Jain, MD, discusses updated data from the phase 3 MEDALIST trial evaluating luspatercept for the treatment of anemic myelodysplastic syndromes.

Olutasidenib Elicits Durable Remissions With/Without Azacitidine in IDH1-Mutant MDS

April 16th 2024

Olutasidenib alone or administered with azacitidine was safe and clinically effective in patients with IDH1-mutated myelodysplastic syndrome.

Dr Sekeres on the Rationale for the FDA Approval of Momelotinib in Myelofibrosis

April 15th 2024

Mikkael A. Sekeres, MD, MS, discusses the background on the FDA approval of momelotinib for the treatment of patients with anemic myelofibrosis.

Dr Ball on the Use of Luspatercept in MDS With Anemia

April 12th 2024

Somedeb Ball, MBBS, discusses the benefits of luspatercept for patients with anemia due to a myelodysplastic syndrome.

Dr Sekeres on Using MDS Risk-Stratification Systems in Clinical Practice

April 12th 2024

Mikkael A. Sekeres, MD, MS, discusses the utility of myelodysplastic syndromes risk stratification systems.

Dr Gangat on the Evolution of JAK Inhibitors in Myelofibrosis

April 12th 2024

Naseema Gangat, MBBS, on evolution of JAK inhibitors for the treatment of patients with myelofibrosis.

Parsaclisib Added to Ruxolitinib Decreases Spleen Volume and Improves Symptom Scores in Myelofibrosis

April 11th 2024

Add-on parsaclisib with ruxolitinib resulted in decreased spleen volume and improved symptom assessment scores in patients with myelofibrosis.

Emerging Treatments for Myelofibrosis

April 10th 2024

Andrew Kuykendall, MD, and Raajit K. Rampal, MD, PhD, conclude that the increasing complexity in myelofibrosis treatment options, including multiple JAK inhibitors and emerging combination therapies, signals an exciting era of individualized care, yet underscores the need for reevaluating study end points to enhance patient outcomes further.

Individualizing Therapy Goals for Patients With Myelofibrosis

April 10th 2024

Andrew Kuykendall, MD, emphasizes the importance of individualizing therapy for patients with myelofibrosis, focusing on improving quality of life and addressing specific issues like anemia and spleen volume, with the understanding that these treatments are palliative and goals should be revisited regularly.

European Commission Approves Frontline Luspatercept for Transfusion-Dependent Anemia in Lower-Risk MDS

April 3rd 2024

The European Commission has expanded its approval of luspatercept to include frontline treatment of transfusion-dependent anemia due to lower-risk MDS.

Selection and Sequencing of JAK Inhibitors for Patients With MF

April 3rd 2024

Raajit K. Rampal, MD, PhD, discusses choosing among JAK inhibitors based on specific patient needs, such as platelet counts and anemia, emphasizing the importance of using the full dose for best efficacy and how different scenarios might influence the choice and sequencing of these drugs in practice.

The FREEDOM-2 Trial: Efficacy and Safety of Fedratinib in Patients With MF Previously Treated With Ruxolitinib

April 3rd 2024

Andrew Kuykendall, MD, discusses the efficacy and adverse effects of fedratinib, highlighting its potential in the second-line setting for patients resistant to ruxolitinib, with updates from FREEDOM-2 emphasizing manageable gastrointestinal tolerability concerns.

Retrospective Study Shows HSCT Consolidation After Blast Reduction Improves OS in Chronic Phase–Reverted MPN

March 27th 2024

Patients with myeloproliferative neoplasms in accelerated or blast phase experience improved survival outcomes after hematopoietic cell transplantation.

Key Efficacy and Safety Takeaways From Recent Data on JAK Inhibitors for MF

March 27th 2024

Drs Rampal and Kuykendall highlight the benefits of pacritinib for patients with low platelet counts, as evidenced by the PERSIST-2 study, and momelotinib for patients with anemia, as shown in the MOMENTUM Phase 3 Study, focusing on their efficacy in spleen volume reduction and symptom relief in patients with myelofibrosis.

Future Directions in Combination Therapies for Myelofibrosis

March 27th 2024

Andrew Kuykendall, MD, and Raajit K. Rampal, MD, PhD, reflect on the future of combination therapies in treating myelofibrosis, emphasizing the need to align study endpoints with treatment goals and highlighting the potential of various combinations based on promising preclinical and early phase study results.